Daria Beshnova
3 Papers
Daria Beshnova is an academic researcher. The author has contributed to research in topics: Immunology & Computer science. The author has co-authored 2 publications.
Chat about Author
Papers
Abstract LB071: A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets
Jenny A. Rudnick,Kiran S. Nadella,Shane Rowley,Ethan Gardner,Shadi Swaidani,Aimee Iberg,Daria Beshnova,Aurora Blucher,Rebecca Sarto Basso,Malini Rajan,Ashraf Abbas Saeed,John H. Ansede,Pouya Hadipour,Kevin W. Jessing,Janet L. Paulsen,Paul Rearden,Vamshi K. Manda,Sashi G. Kasimsetty,Harish Shankaran,Meenakshy Iyer,Ashish Bhandari,Irit Rappley,Laura Schaevitz,Imran Haque,Hayley J. Donnella,Michael F. Cuccarese,Marie Evangelista +26 more
TL;DR: Rudnick et al. as mentioned in this paper combined high-content microscopy with arrayed CRISPR genome editing techniques and machine learning (ML) to build a rigorously controlled dataset enabling exploration of biology and chemistry at scale.
1
Abstract 1888: Identification and optimization of novel small molecule modulators of immune checkpoint resistance with a unified representation space for genomic and chemical perturbations
Ashish Bhandari,Michael F. Cuccarese,Kevin Robert Fales,Kiran S. Nadella,Rebecca Sarto Basso,Daria Beshnova,Hayley J. Donnella,Bahar Shamloo,Jacob C Cooper,Imran Haque,Ron Alfa,Jacob Rinaldi +11 more
TL;DR: This work demonstrates a technique for massively parallel prioritization of new immuno-oncology hypotheses using industrial-scale experimentation and machine learning and highlights multiple discovery programs driven by inferred relationships between small molecules and gene knockout with translation from inference to in vivo efficacy.
Abstract 7133: Phenomics-enabled discovery and optimization of small-molecule RBM39 degraders as an alternative to CDK12 targeting in high-grade serous ovarian cancer (HGSOC)
Chase Neumann,Harish Shankaran,Kiran Nadella,Kelly Biette,Shane Rowley,Ethan Gardner,Shadi Swaidani,Vamshi Manda,Lu Chen,Daria Beshnova,Ashraf Abbas Saeed,Christopher Bailey,Janet Paulsen,Paul Rearden,Carl Brooks,Ashish Bhandari,Christopher Gibson,Laura Schaevitz,Imran Haque,Hayley Donnella,Michael Cuccarese,Marie Evangelista +21 more
TL;DR: Phenomics-enabled discovery and optimization of small-molecule RBM39 degraders as an alternative to CDK12 targeting in high-grade serous ovarian cancer (HGSOC) identifies novel targets and relationships, including a novel association between CDK12 and RBM39, and leads to the identification of REC-1170204, a potent and selective RBM39 degrader with improved potency, selectivity, and drug-like characteristics.